Biotech Stocks Languish After Dismal Quarter of Clinical Results - BNN Bloomberg

688065 Stock   42.02  0.48  1.13%   
About 62% of Cathay Biotech's investor base is looking to short. The analysis of overall sentiment of trading Cathay Biotech stock suggests that many investors are alarmed at this time. The current market sentiment, together with Cathay Biotech's historical and current headlines, can help investors time the market. In addition, many technical investors use Cathay Biotech stock news signals to limit their universe of possible portfolio assets.
  
Biotech Stocks Languish After Dismal Quarter of Clinical Results BNN Bloomberg

Read at news.google.com
Google News at Macroaxis
  

Cathay Biotech Fundamental Analysis

We analyze Cathay Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cathay Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cathay Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Total Debt

Total Debt Comparative Analysis

Cathay Biotech is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Cathay Biotech Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cathay Biotech stock to make a market-neutral strategy. Peer analysis of Cathay Biotech could also be used in its relative valuation, which is a method of valuing Cathay Biotech by comparing valuation metrics with similar companies.

Peers

Cathay Biotech Related Equities

Complementary Tools for Cathay Stock analysis

When running Cathay Biotech's price analysis, check to measure Cathay Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cathay Biotech is operating at the current time. Most of Cathay Biotech's value examination focuses on studying past and present price action to predict the probability of Cathay Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cathay Biotech's price. Additionally, you may evaluate how the addition of Cathay Biotech to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges